Loading patent…
AssigneeOncolytics Biotech Inc.
InventorsPatrick W. K. Lee, James Strong, Matthew C. Coffey
Estimating the term…
Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
A pharmaceutical composition comprising a reovirus, a chemotherapeutic agent and a pharmaceutically acceptable excipient, wherein the chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, mitomycin C, methotrexate, hydroxyurea, cyclophosphamide, dacarbazine, mitoxantrone, epirubicin, doxorubicin, herceptin, etoposide, pregnasome, carboplatin, cisplatin, taxol, taxotere, tamoxifen, anti-estrogens, interferons, aromatase inhibitors, progestational agents and LHRH analogs.
A pharmaceutical composition comprising a reovirus, a chemotherapeutic agent and a pharmaceutically acceptable excipient, wherein the chemotherapeutic agent is not BCNU, wherein the reovirus is formulated in a unit dosage form, and wherein the chemotherapeutic agent is formulated in a unit dosage form.
Dependencies are inferred from the claim text.